Blood plug-intong, Changchun Xiding and other 40 drugs nationwide stop supply! The market for large clinical varieties has shrunk significantly

Pharmaceutical Network July 7th, July 2, Inner Mongolia Medical Insurance Bureau hangs the network "on the summary of the publication of Texas German Pharmaceutical Co., Ltdand other enterprises to apply for the cancellation of part of the drug registration notice." Notice shows that from March 1 to June 30, 2020, due to the rise of raw materials, production line transformation, drug approval was withdrawn and other reasons led to the suspension of many drugs production, Texas German Pharmaceuticals, Shanghai Modern Pharmaceuticals and other 20 pharmaceutical manufacturers (agents) to Inner Mongolia to apply for the cancellation of 40 drugs online eligibility, and submitted a national unified non-supply commitment letter, blood plug-in, Changchun Xitin and other clinical varieties are listed in itSales of large varieties have fallen rapidly
can be seen from the list of drugs listed in Inner Mongolia, Texas German Pharmaceuticals applied for the cancellation of 9 drugs of the network qualification, the number of the most involved enterprises, including after stroke treatment drug injection with Changchun Sitin covers 3 specificationsAccording to Minet.com, the number of enterprises in Changchun Xiding (oral often-released dosage forms, injections) has approved as high as 33 enterprises, with end-sales of more than 4.2 billion yuan in public medical institutions in China in 2018However, in the "First Batch of State Key Monitoring and Rational Drug Use Drugs Catalog (Chemical Drugs and Biological Products)" issued by the National Health and Care Commission in July 2019, 20 generic varieties such as Changchun Xiding were included, and the market for related pharmaceutical hospitals is facing a gradual shrinking dilemmaAccording to Minnet statistics, under the impact of the new crown pneumonia epidemic, the sales amount of 20 varieties (a total of 43 drugs) showed a downward trend, the first quarter of 2020 decreased by 73.36 percent year-on-year, its share of the total amount of chemical drug sales also fell from 6.56 percent in the first quarter of 2018 to 1.75 percent this yearIn the industry's view, Texas DePharmaceutical sinaudo this time to Changchun Xiding application to withdraw the network and make a national non-supply commitment, or in the "abandoned car guard."It is worth noting that cardiovasculardisease
the drug blood plug-in also appeared in the list of drugs in Inner Mongolia, by two pharmaceutical companies submitted a withdrawal application, of which Xi'an Hanfeng Pharmaceutical Seiton two specifications of the blood plug-in injectionIn recent years, with the tightening of the supervision of Chinese medicine injections, the sales of blood plug-in injections in China's public medical institutions have shown negative growth, which has dropped from 6.25 billion yuan in 2016 to 4.32 billion yuan in 2019In addition, the 2019 new National Health Insurance Drug Catalog also adjusted the payment limit for blood plug-in injections, from "limited secondary and above medical institutions" to "limited to secondary and above medical institutions of stroke paraplegia or retinal central vein blockage patients", further reducing the use of blood plug-in injection insurance paymentsIn the industry's view, for a long time, the sales of blood plug-in injections still can not return to the original high peakAt this stage, there are 15 pharmaceutical companies that have a blood plug-in injection approvalDespite the market downturn is difficult to pull, but the blood plug-in is still a veritable large clinical varieties, Xi'an Hanfeng Pharmaceutical siphon is only a momentary helpless action, to continue to pay attention 　　The withdrawal of the standard or the behavior of drug companies to maintenance prices in fact, pharmaceutical companies to apply for withdrawal of the network events occur On May 21, Shanxi Province drug centralized bidding procurement network even issued two withdrawal notice, involving double yellow particles, Qing Kailing injections and other traditional Chinese medicine, as well as hydrochloric acid Benapri tablets, tubmycin drip eye drops, kramycin capsules and other common drugs 66 rules actively apply for the withdrawal of the net On June 22, Gansu Province drug and medical supplies centralized procurement network issued the withdrawal of the network, musk live blood-based ointment, injection osside, emergency syrup, compound katopuri tablets and other 40 enterprises produced 68 drugs also submitted the withdrawal application 　　Indeed, the rising costs, raw material shortage, production line transformation and other uncertainties can directly lead to drug production, especially in the raw material sedative prices are most familiar to the industry The State Administration of Market Supervision and Administration has previously imposed a monopoly on the
distribution of three companies, Shandong Kanghui Pharmaceutical Co., Ltd., Weifang Puyunhui Pharmaceutical Co., Ltd and Weifang Sun Shen Pharmaceutical Co., Ltd., abuse of market dominance, and issued a maximum fine of 325.5 million yuan With the implementation of policies such as the Measures for the Administration of the National List of Drugs in Short Supply (Trial), the enforcement of illegal acts such as the monopoly of API will continue to increase, and the shortage of supply of drugs due to the rapid rise in the price of API will be properly dealt with 　　But there are also senior industry insiders believe that some drugs in a small market share of the province to actively apply for the withdrawal and scrapping of tenders, may also be based on the overall planning of the national market under the maintenance of price behavior, at the expense of smaller market capacity to preserve the overall situation According to the 2017 Statistical Analysis Report on the Operation of the Drug Circulation Industry released by the Ministry of Commerce, Inner Mongolia ranked 29th in the 2017 regional total sales ranking, only higher than tibet and Qinghai provinces To see, the market strategy of the drug companies concerned seems to be so 　　Some experts admitted that if there are pharmaceutical companies determined not to supply in a province, silent exit can be, there is no need to actively apply for the withdrawal of tenders and the withdrawal of prices The logic behind it is clear that, in the industrial environment where drug price linkage is becoming more frequent, pharmaceutical companies may want to wipe out the national price depression However, there is also the view that the withdrawal of the bid may also be the pharmaceutical companies in order to resume production to raise prices in preparation In the national, provincial and local three-level belt procurement normal progress, drug price reduction is irreversible In the pharmaceutical industry under the big waves of sand, some pharmaceutical companies may only in exchange for time for living space